Stockscreener 앱 받기
11.24
4.58%
-0.54
전일 마감가:
$11.78
열려 있는:
$12.15
하루 거래량:
1.38M
Relative Volume:
1.12
시가총액:
$1.09B
수익:
-
순이익/손실:
$-44.84M
주가수익비율:
-23.91
EPS:
-0.47
순현금흐름:
$-44.23M
1주 성능:
-6.49%
1개월 성능:
-16.62%
6개월 성능:
-16.12%
1년 성능:
+50.67%
1일 변동 폭
$11.23
$12.19
1주일 범위
$11.23
$12.43
52주 변동 폭
$7.50
$18.51
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
명칭
Ars Pharmaceuticals Inc
전화
858-771-9307
주소
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
SPRY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
11.24 | 1.09B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-10 | 개시 | Oppenheimer | Outperform |
| 2024-08-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 재확인 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | Raymond James | Outperform |
| 2024-03-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 개시 | William Blair | Outperform |
| 2022-12-13 | 개시 | SVB Leerink | Outperform |
모두보기
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
(SPRY) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Allspring Global Investments Holdings LLC Has $3.63 Million Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Levi & Korsinsky Reminds Shareholders of an Investigation into ARS Pharmaceuticals, Inc. (SPRY) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
Revolutionary Allergy Spray Gets Massive Insurance Breakthrough: Now Covered for Half of US Patients - StockTitan
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® ... - The Bakersfield Californian
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and - GlobeNewswire
Peregrine Capital Management LLC Invests $4.47 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis - MarketBeat
ARS Pharmaceuticals Presents Data On Neffy Epinephrine Nasal Spray At 2025 AAAAI Meeting - Nasdaq
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) ... - The Bakersfield Californian
Revolutionary Needle-Free Allergy Treatment Shows Superior Results: Clinical Data Reveals Game-Changing Efficacy - StockTitan
U.S. Inflation Readings Show Pick Up in Pricing Pressures - The Globe and Mail
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap UpHere's What Happened - MarketBeat
Oppenheimer Initiates Coverage on ARS Pharmaceuticals (NASDAQ:SPRY) - MarketBeat
(SPRY) Technical Data - Stock Traders Daily
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells $615,500.00 in Stock - MarketBeat
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference - GlobeNewswire
ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions - Seeking Alpha
Allergy Treatment Pioneer ARS Pharmaceuticals Takes Center Stage at Major Healthcare Conference - StockTitan
Ars Pharmaceuticals director Laura Shawver sells $615k in stock - MSN
Ars Pharmaceuticals director Laura Shawver sells $615k in stock By Investing.com - Investing.com Australia
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.3%Here's What Happened - MarketBeat
ARS Pharma Rolls Dice Again On NeffyWill Persistence Pay Off? - RTTNews
3 US Growth Stocks With Significant Insider Ownership - Simply Wall St
(SPRY) Investment Report - Stock Traders Daily
ARS Pharmaceuticals (NASDAQ:SPRY) Trading 5.4% HigherStill a Buy? - MarketBeat
Allegations Against ARS Pharmaceuticals, Inc.: Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Reach Out - ACCESS Newswire
Neffy Launches Free Epi Nasal Sprayer Program for U.S. Schools - Allergic Living
Equities Analysts Issue Forecasts for SPRY FY2025 Earnings - MarketBeat
What is William Blair's Estimate for SPRY FY2024 Earnings? - MarketBeat
William Blair Has Bullish Forecast for SPRY Q4 Earnings - MarketBeat
ARS Pharmaceuticals Launches neffyinSchools Program - GlobeNewswire
ARS Pharmaceuticals lays down 2025 objectives for epinephrine nasal spray - MSN
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Lessened by ARS Investment Partners LLC - MarketBeat
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools - The Manila Times
ARS Pharma Launches Free Neffy Nasal Spray Program for U.S. Schools to Combat Allergic Reactions - StockTitan
Cenovus Energy: Analyst Update & AI-Powered Stock Analysis - The Globe and Mail
When (SPRY) Moves Investors should Listen - Stock Traders Daily
Analysts Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Target Price at $26.00 - MarketBeat
Raymond James Issues Positive Forecast for ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up on Analyst Upgrade - MarketBeat
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. - MSN
ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 7.6% After Analyst Upgrade - MarketBeat
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
ARS Pharmaceuticals shares surge on strong Q4 revenue for allergy spray - Investing.com Canada
ARS Pharmaceuticals (NASDAQ:SPRY) Price Target Raised to $27.00 at Leerink Partners - MarketBeat
Ars Pharmaceuticals Inc (SPRY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):